Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.80%, a 11.63% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.30%, a 4.88% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.10%, a 5.13% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.90%, a 129.41% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 0.00% change from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 13.04% decline from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.60%, a 70.37% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.70%, a 170.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.00% 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 4.00% 10-K · filed 2026-03-03 | |||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.10% 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 4.30% 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-03 | |||
| 2024-09-30 | 4.00% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 4.20% 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 4.10% 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | 4.60% 10-K · filed 2025-03-19 | |||
| 2023-09-30 | 3.80% 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 3.80% 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 3.90% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 2.70% 10-K · filed 2024-03-28 | |||
| 2022-09-30 | 2.70% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 2.70% 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 1.70% 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | 1.00% 10-K · filed 2023-03-16 | |||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | 1.10% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.60% 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 0.60% 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | 0.80% 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | 0.80% 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | 2.50% 10-K · filed 2021-03-25 | |||
| 2019-09-30 | 2.50% 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |